We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share. Read more
News
October 2019
January 2017
On 27 January 2017 Synact Pharma presented the company at the Sederemera event in Copenhagen. Read more